Advocacy intelligence hub — real-time data for patient organizations
SWOG Cancer Research Network — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs3
Bavencio
(avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1))Orphan drugstandardEMD Serono Research and Development Institute, Inc.
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tu...
Torisel
(Temsirolimus)Orphan drugstandardWyeth Pharmaceuticals, Inc.
12.1 Mechanism of Action Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12...
Everolimus
(EVEROLIMUS)Orphan drugstandardBreckenridge Pharmaceutical, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pat...
CABOMETYX
(cabozantinib)Orphan drugstandardExelixis, Inc.
12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-...
LENVIMA
(lenvatinib)Orphan drugstandardEisai Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors V...
Nexavar
(sorafenib)Orphan drugstandardBayer HealthCare Pharmaceuticals, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple int...
Votrient
(pazopanib)Orphan drugstandardNovartis Pharmaceuticals Corp
12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, pl...
Comparative optical characterization of renal cell carcinoma.
Accurate characterization of the optical properties of renal cell carcinoma (RCC) tissue is essential for reliable modeling of light–tissue interactions in laser-based diagnostic and therapeuti...
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.
Adjuvant pembrolizumab improved disease-free survival (DFS) and overall survival (OS) versus placebo in participants with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy i...
The IQGAP1-Claudin4-JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma.
Renal cell carcinoma (RCC) is a highly heterogeneous malignant neoplasm with multiple morphological and molecular subtypes; however, the basis of this heterogeneity remains incompletely defined, hinde...
NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma.
Cancer-associated fibroblasts (CAF) are abundant stromal cells in the tumor microenvironment (TME) that play a vital role in promoting tumor progression and drug resistance. The mechanisms regulating ...
PIK-III-Mediated Elevation of Thiamine Re-Sensitises Renal Cell Carcinoma to Cuproptosis via Activating PDHA1.
Cuproptosis, a copper-dependent cell death mechanism driven by tricarboxylic acid (TCA) cycle collapse, shows limited efficacy in hypoxic or glycolytic renal cell carcinoma (RCC). Here, through system...
Biomarkers for renal cell carcinoma - a pragmatic approach.
Biomarkers for renal cell carcinoma - a pragmatic approach.
Eric Jonasch, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Daniel George, MD
Duke University
Giuseppe Procopio, MD, R. Ph
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
📍 RAHWAY, NJ
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Robert J Amato, MD
The Methodist Hospital Research Institute
Robert J Amato, DO
Baylor College of Medicine - Methodist Hospital